title: Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease.
abstract: OBJECTIVE
  Eradication of Helicobacter pylori is known to reduce ulcer recurrence in patients with peptic ulcer disease, however, other long-term effects after eradication therapy are not well known. The aim of this study is to examine the long-term effect of H. pylori eradication on clinical symptoms, quality of life, body mass index, newly emerging symptoms, and newly developed diseases.
  
  
  METHODS
  One hundred and ninety-two Japanese patients with peptic ulcer disease who received H. pylori eradication therapy at Department of Gastroenterology, Osaka City University Hospital between 1993 and 1995 were asked to fill in specially a prepared questionnaire.
  
  
  RESULTS
  One hundred and fourteen patients returned the questionnaires; out of them 98 could be analyzed in this study. Successful eradication (n = 88) resulted in alleviation of symptoms, improvement of quality of life and increase of body mass index while failure of eradication (n = 10) had much less or no effects. A relatively high incidence of hyperlipidemia (25.0%) was observed in patients with successful H. pylori eradication. Development of hyperlipidemia was associated with significant improvement of quality of life especially the item concerning eating and drinking habits but not with increased body mass index. In the elderly, no significant change in body mass index was observed, however, post-eradication body mass index was significantly higher in patients with hyperlipidemia than those without.
  
  
  CONCLUSIONS
  Cure of H. pylori infection alleviates symptoms and improves quality of life of treated patients, but might be associated with an increased incidence of hyperlipidemia.
authors.affiliation: Department of Gastroenterology, Osaka City University Medical School, 1-4-3 Asahimachi, Abenoku, Osaka 545-8585, Japan. yasu@med.osaka-cu.ac.jp
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Higuchi
authors.forename: Usama A
authors.initials: UA
authors.lastname: Arafa
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Uchida
authors.forename: Kazunari
authors.initials: K
authors.lastname: Tominaga
authors.forename: Toshio
authors.initials: T
authors.lastname: Watanabe
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Arakawa
mesh_terms: D015992:Body Mass Index; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology; D011788:Quality of Life
chemical_list: D009853:Omeprazole